Articles On Amplia Therapeutics (ASX:ATX)
Title | Source | Codes | Date |
---|---|---|---|
Amplia Therapeutics and Patrys outline unique cancer drugs at Proactive Lifesciences Webinar
Both Amplia and Patrys have flagship drugs in development that take unique approaches to tackling cancers. |
Proactive Investors | ATX | 3 years ago |
Closing Bell: ASX defies the odds to finish in positive territory
The ASX was set for another negative day if futures and Wall Street’s drop were any guide — but even with a bad start, Australia’s bourse finished in the green. The ASX 200 fell as much as 0.50% in the first few minutes of trade but closed... |
Stockhead | ATX | 3 years ago |
Amplia Therapeutics shifts from pre-clinical to drug development with two potent candidates for cancer and fibrotic diseases treatment
It is developing two proprietary, orally available, small molecule Focal Adhesion Kinase inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. |
Proactive Investors | ATX | 3 years ago |
Amplia Therapeutics details upcoming Phase 2 pancreatic cancer trial
|
Proactive Investors | ATX | 3 years ago |
Amplia Therapeutics to conduct Phase 2 trial for Focal Adhesion Kinase inhibitor AMP945 in first line pancreatic cancer patients
The pharmaceutical company plans to initiate patient recruitment at Australian sites in the first quarter of 2022. |
Proactive Investors | ATX | 3 years ago |
Miners fuel ASX fall at open, BHP, RIO, FMG trading in red
Highlights The ASX 200 fell 18.7 points or 0.25% to 7,418.6 in the opening session, while the ASX All ordinaries index was 0.24% down at 7,722.1. The market breadth is extremely weak so far today, with 10 out of the 11 sectors trad... |
Kalkine Media | ATX | 3 years ago |
ASX Health Stocks: Amplia begins Phase 2 trial for pancreatic cancer, while Avecho commences Phase 1 of cannabis gel
The ASX 200 health stocks index (XHJ) has lifted by 0.19% at the time of writing, compared to the broader ASX 200 index which fell by 0.70%. The cancer and fibrosis focused company, Amplia Therapeutics (ASX:ATX), has completed the design fo... |
Stockhead | ATX | 3 years ago |
Amplia Therapeutics completes design of Phase 2 AMP945 trial to treat advanced pancreatic cancer
Australian pharmaceutical company Amplia Therapeutics (ASX: ATX) has completed the design for a Phase 2 clinical trial of its focal adhesion kinase (FAK) inhibitor AMP945 for the treatment of advanced pancreatic cancer. The design is based... |
SmallCaps | ATX | 3 years ago |
Directors’ Trades: Otto Buttula buys another $580k of Rhythm Biosciences shares
Just under two years since Otto Buttula became chairman of Rhythm Biosciences (ASX:RHY), it has gained over 500% since – and the boss of the high flying biotech just chipped more in. Buttula, who in the past has headed financial services fi... |
Stockhead | ATX | 3 years ago |
Closing Bell: A red-hot IPO, possible pump and dump, and the Big Australian goes ex-divvie
The ASX 200 finished in the red today, as the big end of town played second fiddle to the microcap Emerging Companies index which posted a solid ~0.7% gain. Mining stocks dragged on the broader index, as BHP (ASX:BHP) traded ex-dividend (it... |
Stockhead | ATX | 3 years ago |
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August
Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat... |
Stockhead | ATX | 3 years ago |
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress
It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N... |
Stockhead | ATX | 3 years ago |
Check Up: Hexima roars 70pc on clinical trials, while Bionomics heads for a US dual listing
The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du... |
Stockhead | ATX | 3 years ago |
Amplia Therapeutics prepares for phase two AMP945 trial backed by shareholders
Amplia Therapeutics (ASX: ATX) will be spending the September quarter finalising the design of phase two clinical trials of its lead drug AMP945 in both pancreatic cancer and idiopathic lung fibrosis (IPF) patients. This work is being suppo... |
SmallCaps | ATX | 3 years ago |
Amplia Therapeutics phase 1 results support development of AMP945 in cancer and fibrosis
Pharmaceutical company Amplia Therapeutics (ASX: ATX) has announced the unblinded results of a phase one clinical trial that supports further development of its drug AMP945 in cancer and fibrosis. The results confirmed the company’s prelimi... |
SmallCaps | ATX | 3 years ago |
Market Highlights and 5 ASX Small Caps to watch on Wednesday
Wall Street, European stocks rebound on the dip All three US benchmarks rallied overnight, along with the European sharemarkets as investors bought the dip. The Dow Jones rose 1.62%, S&P 500 by 1.52%, while the Nasdaq rose by 1.57%. The... |
Stockhead | ATX | 3 years ago |
Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down
It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by Rhinomed (ASX:RNO)... |
Stockhead | ATX | 3 years ago |
Check up: A mixed bag for ASX health stocks as FDA decides fates at the flip of a coin
It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals... |
Stockhead | ATX | 3 years ago |
Amplia Therapeutics partners with Garvan Institute to develop pancreatic cancer drug
Pharmaceutical company Amplia Therapeutics (ASX: ATX) has finalised a deal with the Garvan Institute of Medical Research in Sydney to collaborate on the development of Amplia’s drug AMP945 to treat patients with pancreatic cancer. The Melbo... |
SmallCaps | ATX | 3 years ago |
Amplia Therapeutics and Sydney’s Garvan Institute enter collaboration agreement for pancreatic cancer treatment
Amplia Therapeutics is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. |
Proactive Investors | ATX | 3 years ago |
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed
Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U... |
Stockhead | ATX | 3 years ago |
Closing Bell: Today’s biggest small cap movers on the ASX
Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad... |
Stockhead | ATX | 3 years ago |
Why the Amplia (ASX:ATX) share price is rocketing 41% higher today
The Amplia Therapeutics Ltd (ASX: ATX) share price is one of the best performers on the ASX today. This comes after the pharmaceutical company announced positive news in trials to improve pancreatic cancer survival. At one point in intrada... |
Motley Fool | ATX | 3 years ago |
Five penny stocks packing a punch today
Summary Amplia Therapeutics has received promising data from its Focal Adhesion Kinase inhibitor in the treatment of cancer. Spectur expects to post a record revenue of approximately AU$1.8 million in Q4. Douugh has formed a strategic... |
Kalkine Media | ATX | 3 years ago |
Positive clinical data sends Amplia Therapeutics nearly 50 per cent up
Biotech Amplia Therapeutics (ASX:ATX) was one of this morning’s biggest winners after positive clinical data. The company has a drug fighting cancer, AMP945, that inhibits Focal Adhesion Kinase (FAK). FAK is a protein that is over-expressed... |
Stockhead | ATX | 3 years ago |
10 at 10: These ASX stocks have risen to the skies this morning
Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov... |
Stockhead | ATX | 3 years ago |
Amplia Therapeutics updates on data from cancer collaboration
Amplia Therapeutics (ASX:ATX) says it has received new data from its collaboration with Professor Paul Timpson of the Garvan Institute of Medical Research in Sydney. |
BiotechDispatch | ATX | 3 years ago |
Invion led a group of ASX cancer stocks up after promising news
It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX... |
Stockhead | ATX | 3 years ago |
ScoPo’s Powerplays: Health sector trades sideways but M&A plays coloured the week
Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Themes of the week Healthcare f... |
Stockhead | ATX | 3 years ago |
Closing Bell: Today’s biggest small cap movers on the ASX
Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scr... |
Stockhead | ATX | 3 years ago |
Last Orders: The ASX starts the week slightly higher
After gaining 0.5 per cent in the first hour of trade the ASX only finished slightly upwards. The ASX 200 closed at 7,029 points, which was 0.04 per cent higher than Friday. Small caps had a worse day – the ASX Emerging Companies Index clos... |
Stockhead | ATX | 3 years ago |
Last Orders: Despite losing week, best month in six for small caps
Small caps have declined for the fourth time in the past five days — but still finished April with their strongest performance in six months. The Small Ordinaries index gained 4.83 per cent in April despite declining 0.96 per cent this week... |
Stockhead | ATX | 3 years ago |
Here’s why ASX healthcare shares OCC and ADO were trending today
Summary Regenerative medicine player Orthocell has announced positive results from the US 510(k) animal pilot study of CelGro®. AnteoTech has obtained firm commitments to raise AU$12M to accelerate its test product pipeline. Althou... |
Kalkine Media | ATX | 3 years ago |
Respiri (ASX:RSH) shares flying high on TerryWhite Chemmart partnership
Summary Respiri Limited has partnered with Australia’s largest pharmacy network, TerryWhite Chemmart, for the sale and marketing of wheezo™. This agreement brings the total number of pharmacies contracted to stock and sell wheezo to 1,... |
Kalkine Media | ATX | 3 years ago |
Why were Australian healthcare shares EX1 and RAC trending today?
Summary Exopharm obtained firm commitments from institutional and sophisticated investors to raise a total of AU$12 million. Race Oncology announced that its new Chief Medical Officer, Dr David Fuller, is set to join on 1 July 2021.... |
Kalkine Media | ATX | 3 years ago |
Why are Amplia Therapeutics (ASX:ATX) shares flying high today?
Summary Amplia Therapeutics has obtained data from an animal study demonstrating its FAK inhibitors lower fibrosis arising from the NASH. The positive data from the animal study is anticipated to support the future development and part... |
Kalkine Media | ATX | 3 years ago |
10 at 10: These ASX stocks have made surprising growth this morning
Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov... |
Stockhead | ATX | 3 years ago |
Why are Australian MedTech penny shares TTB and UBI trending today?
Source: REDPIXEL.PL, Shutterstock Summary Total Brain introduced discrete & continuous HRV functionality to its existing mental health self-monitoring and self-care platform. Electrochemical strips developer Universal Biosensors I... |
Kalkine Media | ATX | 3 years ago |
Amplia completes dosing in phase one study of AMP945
Amplia Therapeutics (ASX:ATX), a company developing new drugs for the treatment for cancer and fibrosis, has announced it has successfully completed the dosing of subjects in its phase one clinical trial of its focal adhesion kinase... |
BiotechDispatch | ATX | 3 years ago |
Market highlights and 5 ASX small caps to watch on Thursday
Wall Street at record highs again after Fed speech US stocks rose to record highs again after the US Federal Reserve decided to keep rates at near zero until 2023. Fed chairman Jerome Powell said that he expected growth for 2020 to be 6.5 p... |
Stockhead | ATX | 3 years ago |
Check Up: Oneview leads healthcare sector after ‘investor awareness’ pact
Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return... |
Stockhead | ATX | 3 years ago |
Three ASX penny stocks in the healthcare space – OCC, ATX and EMD
Source: Guschenkova, Shutterstock Summary Amid the detrimental impact of the ongoing pandemic, the healthcare sector has continued to witness new heights. Penny stocks are grabbing attention from market participants as they are low-pr... |
Kalkine Media | ATX | 3 years ago |
Here’s why the Amplia (ASX:ATX) share price is up 9% today
The Amplia Therapeutics Ltd (ASX: ATX) share price is running higher today following the initiation of a multiple-dose study using AM945. During late-morning trade, shares in the Australian pharmaceutical company are up 7% to 29 cents. Amp... |
Motley Fool | ATX | 3 years ago |
Amplia Therapeutics takes Australian cancer discovery into trials
Melbourne-based ASX-listed biotechnology company Amplia Therapeutics (ASX:ATX) will develop a potential new pancreatic cancer therapy discovered by scientists at the Cancer Therapeutics CRC. |
BiotechDispatch | ATX | 4 years ago |
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone
|
Proactive Investors | ATX | 4 years ago |
ScoPo’s Health Powerplays: The money keeps flowing for the ASX biotechs
Shareholders in Antisense Therapeutics, Amplia Therapeutics and Immutep all had reason to smile this week A trio of capital raisings ... Read More The post ScoPo’s Health Powerplays: The money keeps flowing for the ASX biotechs appeared fir... |
Stockhead | ATX | 4 years ago |
Amplia Therapeutics Ltd - Amplia Receives Human Research Ethics Committee Clearance to Conduct Phase 1 Clinical Trial
Our summary of Amplia Therapeutics Ltd's recent announcement What's happened? Amplia Therapeutics Limited (ASX: ATX, "Amplia") has received clearance from the Alfred Hospital Human Research Ethics Committee (HREC) to conduct a Phase 1 clini... |
SmallCapInsider | ATX | 4 years ago |
Amplia Therapeutics Ltd - Amplia Appoints Dr Mark Devlin as Chief Scientific Officer
Our summary of Amplia Therapeutics Ltd's recent announcement What's happened? Amplia Therapeutics Limited (ASX: ATX, "Amplia") has announced that it has appointed Dr. Mark Devlin as the company's Chief Scientific Officer. What are the key h... |
SmallCapInsider | ATX | 4 years ago |
ASX capital raisings top $30b in 2020 so far
ASX companies continued to raise money in July, with over $4bn shelled out by investors, taking 2020’s total above $30bn. According to Bloomberg, there has been $32.3bn worth of cash raised between January 1 and August 3. This is well ahead... |
Stockhead | ATX | 4 years ago |
Amplia Therapeutics Ltd - Amplia Appoints Nucleus Network to Conduct Phase 1 Clinical Trial
Our summary of Amplia Therapeutics Ltd's recent announcement What's happened? Amplia Therapeutics Limited (ASX: ATX) has appointed the Nucleus Network in Melbourne to conduct its upcoming Phase 1 clinical trial testing AMP945, the Company’s... |
SmallCapInsider | ATX | 4 years ago |